Statin Therapy Management

Introduction to Statin Therapy

Statin therapy is recommended for patients with high cardiovascular risk, with benefits outweighing risks, including mild CK elevation, especially in patients with diabetes, according to the American College of Cardiology 1

The European Society of Cardiology recommends that mild CK elevations (<3x ULN) without symptoms do not require statin discontinuation 2
The American College of Cardiology states that the cardiovascular benefit of statin therapy likely outweighs the risk of mild CK elevation, especially in patients with diabetes 1

The American College of Cardiology suggests that if a patient reports muscle pain, weakness, or tenderness, another CK measurement should be obtained and temporary discontinuation of statin therapy should be considered only if symptoms are bothersome 1
Routine laboratory monitoring of creatine kinase (CK) is not recommended in asymptomatic patients after starting statin therapy and should only be performed when patients report muscle symptoms, according to the American College of Cardiology 3
A baseline CK measurement before initiating statin therapy is recommended by the American College of Cardiology (ACC) to aid in later clinical decision-making, as asymptomatic CK elevations are common 3
Baseline creatine phosphokinase (CPK) measurement should be taken before initiating lipid-lowering therapy, with follow-up measurements 4-6 weeks after starting therapy, and more frequent monitoring for high-risk patients, including the elderly, those with multiple medications, history of muscle symptoms, or renal impairment 4, 5, 3

Evaluate CPK levels to determine severity, with normal CPK indicating mild (Grade 1) myalgias, CPK 3-10× upper limit of normal (ULN) indicating moderate (Grade 2) myalgias, and CPK >10× ULN or severe symptoms indicating severe (Grade 3-4) myalgias 6
Consider alternative causes of muscle weakness, including hypothyroidism, reduced renal or hepatic function, rheumatologic disorders, vitamin D deficiency, primary muscle diseases, and recent strenuous exercise or work, in patients on lipid-lowering therapy 1, 3

For patients reporting muscle symptoms, the American College of Cardiology recommends obtaining a CK measurement immediately, comparing to baseline CK level, and checking thyroid-stimulating hormone (TSH) level to rule out hypothyroidism as a predisposing factor 3
Consider symptomatic treatment, including NSAIDs if no contraindications, and magnesium supplementation (300-400 mg elemental magnesium daily) 4, 5, 7
If myositis is confirmed, hold lipid-lowering therapy temporarily and initiate prednisone 0.5-1 mg/kg/day if moderate symptoms, with consideration of higher dose steroids (1-2 mg/kg/day) for severe cases 4, 5
For mild to moderate symptoms, temporarily discontinuing statin for 2-4 weeks until symptoms resolve, then rechallenging with the same statin at a lower dose, an alternative statin, or an alternative dosing regimen may be effective 7, 6

Patients with renal or hepatic dysfunction are at higher risk for statin-associated myopathy 8
Concomitant medications that increase statin myopathy risk include fibrates, cyclosporine, azole antifungals, macrolide antibiotics, and HIV protease inhibitors 8
Consider alternative statins with lower myopathy risk, such as fluvastatin or pravastatin, or alternate-day dosing of atorvastatin, if symptoms persist despite dose reduction 3
Adding ezetimibe to a lower statin dose may be considered to maintain LDL-lowering efficacy 3
Elderly patients (age >65 years) should be closely monitored for the development of muscle symptoms, even with mildly elevated CPK levels, due to their increased risk of statin-associated myopathy 3
The nocebo effect, where up to 90% of muscle symptoms may be attributable to the expectation of side effects rather than the statin itself, should not be overlooked in patients taking statins 7

The European Association for the Study of Diabetes recommends considering GLP-1 receptor agonists as they improve both glycemic control and cardiovascular outcomes, and SGLT2 inhibitors may be beneficial, especially if cardiovascular or renal disease is present 9
The American Heart Association suggests continuing PCSK9 inhibitor therapy in patients with elevated CPK levels, as evidence shows 92% of patients had reduction in CPK levels after starting PCSK9 inhibitors, with 46% having CPK levels return to normal 4, 5
PCSK9 inhibitors like Repatha are safe and effective even in patients with markedly elevated CPK levels, with evidence showing no serious adverse reactions and only 2 patients discontinuing treatment (not due to muscle symptoms) 4, 5

The European Society of Cardiology recommends annual lipid profile and A1c monitoring if stable, and continued monitoring for muscle symptoms at each visit 2
Risk factors for increased myalgia in patients taking statins include advanced age (especially >80 years), female sex, small body frame and frailty, multiple medications, and perioperative periods 3